The earnings call reveals financial challenges, with cash reserves declining and significant net losses due to increased R&D expenses. While there is optimism about dystrophin levels in trials, uncertainties exist regarding patient recruitment and trial timelines. The Q&A section highlights operational and scientific risks, with management providing vague responses on key timelines and regulatory endpoints. Despite potential positive outcomes in therapy development, the financial strain and lack of clear guidance create a negative sentiment. The absence of a market cap further complicates the assessment, leading to a prediction of a negative stock price movement.
